JAC Advance Access originally published online on November 11, 2005
Journal of Antimicrobial Chemotherapy 2006 57(1):4-7; doi:10.1093/jac/dki411
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leading article |
HIV infection in older patients in the HAART era
1 Service de Biostatistique et Informatique Médicale, Université Paris-Descartes, Faculté de Médecine, Hôpital Cochin, Paris, France; 2 Unité 720 INSERM et Université Pierre et Marie Curie, Paris, France; 3 Department of Clinical Immunology, Université Paris-Descartes, Faculté de Médecine, Hôpital Européen Georges Pompidou, Paris, France
* Correspondence address. Hôpital Cochin, Service de Biostatistique et Informatique Médicale, 27 Rue du Fg St Jacques, 75 679 Paris CEDEX 14, France. Tel: +33-1-58-41-20-24 (direct)/+33-1-58-41-31-54 (secretary); Fax: +33-1-58-41-19-61; E-mail: grabar{at}cochin.univ-paris5.fr
An increasing number of patients over 50 years of age are now living with HIV, owing to highly active antiretroviral therapy (HAART) that prolongs survival on the one hand and to late diagnosis of patients living with occult HIV infection on the other hand. Most studies have shown that compared with younger patients, patients over 50 generally have a slower immunological response to HAART and experience more rapid clinical progression, despite a better virological response. Low thymic output probably plays a role in the poorer CD4 cell response in patients initiating HAART over 50 years. Management of HIV infection in older patients is particularly complex, mainly because they are more likely to have co-morbidities necessitating specific medications that may interact with antiretroviral drugs. More controlled studies of HAART efficacy and tolerability in such patients are needed to establish specific management guidelines. Information campaigns targeting older patients and their doctors are also needed to ensure timely diagnosis of HIV infection and antiretroviral treatment initiation.
Keywords: antiretroviral treatment , elderly , HIV/AIDS
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. D. Sanders, A. M. Bayoumi, M. Holodniy, and D. K. Owens Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med, June 17, 2008; 148(12): 889 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Amano, Y. Koh, D. Das, J. Li, S. Leschenko, Y.-F. Wang, P. I. Boross, I. T. Weber, A. K. Ghosh, and H. Mitsuya A Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI), GRL-98065, Is Potent against Multiple-PI-Resistant Human Immunodeficiency Virus In Vitro Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2143 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Torti, G. Lapadula, P. Barreiro, V. Soriano, S. Mandalia, A. De Silvestri, F. Suter, F. Maggiolo, A. Antinori, F. Antonucci, et al. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load J. Antimicrob. Chemother., June 1, 2007; 59(6): 1141 - 1147. [Abstract] [Full Text] [PDF]
|
|